HAVCR2 and cancer: T cell activation is typical in both cancer progression (36), among others, in NSCLC (37, 38) and pneumonitis (39) due to persistent T cell receptor stimulation and is accompanied by the expression of inhibitory receptors such as PD-1 and TIM-3 (40–42) and T cell dysfunction (40).